Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor

Yingjie Wu, Hui (Herb) Sun, Jelena Basta-Pljakic, Luis Cardoso, Oran D. Kennedy, Hector Jasper, Horacio Domené, Liliana Karabatas, Clara Guida, Mitchell B. Schaffler, Clifford J. Rosen, Shoshana Yakar

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

States of growth hormone (GH) resistance, such those observed in Laron dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout [GHRKO]) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects on the skeleton that are independent of serum or tissue IGF-1, and poor delivery of IGF-1 to the tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in patients with Laron syndrome does not achieve full skeletal growth.

Original languageEnglish (US)
Pages (from-to)1575-1586
Number of pages12
JournalJournal of Bone and Mineral Research
Volume28
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Somatotropin Receptors
Insulin-Like Growth Factor I
Serum
Growth Hormone
Transgenes
Growth
Liver
Laron Syndrome
Glucose Intolerance
Adiposity
Skeleton
Knockout Mice
Homeostasis
Phenotype
Gene Expression
Glucose
Mutation

Keywords

  • BETA-ISLET
  • BONE
  • GLUCOSE TOLERANCE
  • GROWTH HORMONE RECEPTOR
  • IGF-1
  • MICRO-COMPUTED TOMOGRAPHY

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. / Wu, Yingjie; Sun, Hui (Herb); Basta-Pljakic, Jelena; Cardoso, Luis; Kennedy, Oran D.; Jasper, Hector; Domené, Horacio; Karabatas, Liliana; Guida, Clara; Schaffler, Mitchell B.; Rosen, Clifford J.; Yakar, Shoshana.

In: Journal of Bone and Mineral Research, Vol. 28, No. 7, 07.2013, p. 1575-1586.

Research output: Contribution to journalArticle

Wu, Y, Sun, HH, Basta-Pljakic, J, Cardoso, L, Kennedy, OD, Jasper, H, Domené, H, Karabatas, L, Guida, C, Schaffler, MB, Rosen, CJ & Yakar, S 2013, 'Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor', Journal of Bone and Mineral Research, vol. 28, no. 7, pp. 1575-1586. https://doi.org/10.1002/jbmr.1920
Wu, Yingjie ; Sun, Hui (Herb) ; Basta-Pljakic, Jelena ; Cardoso, Luis ; Kennedy, Oran D. ; Jasper, Hector ; Domené, Horacio ; Karabatas, Liliana ; Guida, Clara ; Schaffler, Mitchell B. ; Rosen, Clifford J. ; Yakar, Shoshana. / Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. In: Journal of Bone and Mineral Research. 2013 ; Vol. 28, No. 7. pp. 1575-1586.
@article{ba1e0b10865e4bad99d4f740f5d81902,
title = "Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor",
abstract = "States of growth hormone (GH) resistance, such those observed in Laron dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout [GHRKO]) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects on the skeleton that are independent of serum or tissue IGF-1, and poor delivery of IGF-1 to the tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in patients with Laron syndrome does not achieve full skeletal growth.",
keywords = "BETA-ISLET, BONE, GLUCOSE TOLERANCE, GROWTH HORMONE RECEPTOR, IGF-1, MICRO-COMPUTED TOMOGRAPHY",
author = "Yingjie Wu and Sun, {Hui (Herb)} and Jelena Basta-Pljakic and Luis Cardoso and Kennedy, {Oran D.} and Hector Jasper and Horacio Domen{\'e} and Liliana Karabatas and Clara Guida and Schaffler, {Mitchell B.} and Rosen, {Clifford J.} and Shoshana Yakar",
year = "2013",
month = "7",
doi = "10.1002/jbmr.1920",
language = "English (US)",
volume = "28",
pages = "1575--1586",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor

AU - Wu, Yingjie

AU - Sun, Hui (Herb)

AU - Basta-Pljakic, Jelena

AU - Cardoso, Luis

AU - Kennedy, Oran D.

AU - Jasper, Hector

AU - Domené, Horacio

AU - Karabatas, Liliana

AU - Guida, Clara

AU - Schaffler, Mitchell B.

AU - Rosen, Clifford J.

AU - Yakar, Shoshana

PY - 2013/7

Y1 - 2013/7

N2 - States of growth hormone (GH) resistance, such those observed in Laron dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout [GHRKO]) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects on the skeleton that are independent of serum or tissue IGF-1, and poor delivery of IGF-1 to the tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in patients with Laron syndrome does not achieve full skeletal growth.

AB - States of growth hormone (GH) resistance, such those observed in Laron dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout [GHRKO]) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects on the skeleton that are independent of serum or tissue IGF-1, and poor delivery of IGF-1 to the tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in patients with Laron syndrome does not achieve full skeletal growth.

KW - BETA-ISLET

KW - BONE

KW - GLUCOSE TOLERANCE

KW - GROWTH HORMONE RECEPTOR

KW - IGF-1

KW - MICRO-COMPUTED TOMOGRAPHY

UR - http://www.scopus.com/inward/record.url?scp=84879213467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879213467&partnerID=8YFLogxK

U2 - 10.1002/jbmr.1920

DO - 10.1002/jbmr.1920

M3 - Article

VL - 28

SP - 1575

EP - 1586

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 7

ER -